American Journal of Clinical Pathology · 2015 · 14 citations · 36 references
MedicineOncologyPathologyMolecular OncologyNeoplasiaTumor ProgressionCancer Molecular PathologyImmunohistochemistryMelanocytic TumorsMolecular Tumor ProfilingNonmelanocytic Skin TumorsSkin TumorsImmunohistochemical BiomarkersImmunohistochemical DetectionImmunohistochemical MarkersImmunohistochemical StainingMalignant Melanocytic TumorsMelanocytic Tumor PrognosisMelanoma BiomarkersTumor Invasion Assessment
OBJECTIVES: This study examines the expression and the role of four-and-a-half LIM domains protein 2 (FHL2) and transforming growth factor β1 (TGF-β1) in human malignant melanoma. It is determined whether both proteins influence melanoma survival time. METHODS: We analyzed the immunohistochemical staining intensities of FHL2 and TGF-β1 in normal skin and in 50 malignant melanomas with different mutation status (BRAF-V600E, NRAS codon 61 mutation, and wild type). Survival data were available for 45 cases. RESULTS: In melanocytes of nonneoplastic human skin, FHL2 expression was absent. In contrast, 38 (76%) of 50 melanomas showed strong cytoplasmic and partly nuclear FHL2 expression. At the invasion front, cytoplasmic TGF-β1 staining was observed in 32 (64%) of 50 melanomas, and a correlation of FHL2 and TGF-β1 staining intensities was detectable. In follow-up analyses, enhanced FHL2 and TGF-β1 staining intensities in the tumor invasion front were associated with poor survival. CONCLUSIONS: Enhanced FHL2 and TGF-β1 expression is correlated with poor survival in human malignant melanoma. Protumorigenic effects of autocrine TGF-β1 secretion might be exerted by induction of FHL2 expression in melanoma cells. Since melanomas treated with targeted therapies often do not show sufficient response rates, inhibition of FHL2 and/or TGF-β1 might be a promising therapeutic approach.
36
Final Version of 2009 AJCC Melanoma Staging and Classification
Charles M. Balch, Jeffrey E. Gershenwald, Seng-Jaw Soong et al. · Journal of Clinical Oncology · 2009 · 4.6K citations · Full text
Increasing Burden of Melanoma in the United States
Eleni Linos, Susan M. Swetter, Myles Cockburn et al. · Journal of Investigative Dermatology · 2009 · 774 citations · Full text
Medicine, Dermatology, Oncology +12
B-RAF is a therapeutic target in melanoma
Maria Karasarides, Antonio Chiloeches, Robert Hayward et al. · Oncogene · 2004 · 433 citations
Medicine, Cancer Biology, Oncology +12
FHL2, a novel tissue‐specific coactivator of the androgen receptor
The EMBO Journal · 2000 · 327 citations · Full text